FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966393463> ?p ?o ?g. }

• W1966393463 endingPage "2050" @default.
• W1966393463 startingPage "2047" @default.
• W1966393463 abstract "Objective To determine whether infectious trachoma can be completely eliminated from severely affected villages. Design Cross-sectional survey of 2 villages previously enrolled and monitored over 42 months as part of a larger, group-randomized clinical trial. Participants A total of 758 individuals residing in 2 villages with high baseline trachoma prevalence, of a total population of 768 (98.7%). Methods All members of the 2 villages were offered 6 biannual mass treatments with oral azithromycin. At 42 months, each current village member was examined. The right upper tarsal conjunctiva was everted and swabbed. Samples were processed for evidence of Chlamydia trachomatis RNA. Main Outcome Measures Clinical activity by World Health Organization simplified grading scale for trachoma and laboratory evidence of chlamydial RNA. Results Average antibiotic coverage over the study period was 90% and 94% in the 2 villages. Clinical trachoma activity in children aged 1 to 5 years decreased from 78% and 83% in the 2 villages before treatment to 17% and 24% at 42 months. Polymerase chain reaction (PCR) evidence of infection in the same age group decreased from 48% to 0% in both villages at 42 months. When all age groups were examined, there were zero cases with evidence of chlamydial RNA among 758 total villagers tested. Conclusions Biannual mass distribution of azithromycin can locally eliminate ocular chlamydial infection from severely affected communities. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article. To determine whether infectious trachoma can be completely eliminated from severely affected villages. Cross-sectional survey of 2 villages previously enrolled and monitored over 42 months as part of a larger, group-randomized clinical trial. A total of 758 individuals residing in 2 villages with high baseline trachoma prevalence, of a total population of 768 (98.7%). All members of the 2 villages were offered 6 biannual mass treatments with oral azithromycin. At 42 months, each current village member was examined. The right upper tarsal conjunctiva was everted and swabbed. Samples were processed for evidence of Chlamydia trachomatis RNA. Clinical activity by World Health Organization simplified grading scale for trachoma and laboratory evidence of chlamydial RNA. Average antibiotic coverage over the study period was 90% and 94% in the 2 villages. Clinical trachoma activity in children aged 1 to 5 years decreased from 78% and 83% in the 2 villages before treatment to 17% and 24% at 42 months. Polymerase chain reaction (PCR) evidence of infection in the same age group decreased from 48% to 0% in both villages at 42 months. When all age groups were examined, there were zero cases with evidence of chlamydial RNA among 758 total villagers tested. Biannual mass distribution of azithromycin can locally eliminate ocular chlamydial infection from severely affected communities." @default.
• W1966393463 created "2016-06-24" @default.
• W1966393463 creator A5014277100 @default.
• W1966393463 creator A5020252832 @default.
• W1966393463 creator A5021420755 @default.
• W1966393463 creator A5030170309 @default.
• W1966393463 creator A5031739654 @default.
• W1966393463 creator A5037773842 @default.
• W1966393463 creator A5043697434 @default.
• W1966393463 creator A5056077950 @default.
• W1966393463 creator A5070236238 @default.
• W1966393463 creator A5075952432 @default.
• W1966393463 creator A5080095497 @default.
• W1966393463 creator A5083184324 @default.
• W1966393463 date "2009-11-01" @default.
• W1966393463 modified "2023-09-23" @default.
• W1966393463 title "Complete Local Elimination of Infectious Trachoma from Severely Affected Communities after Six Biannual Mass Azithromycin Distributions" @default.
• W1966393463 cites W1506988394 @default.
• W1966393463 cites W163854424 @default.
• W1966393463 cites W1966251114 @default.
• W1966393463 cites W1972601065 @default.
• W1966393463 cites W1989285913 @default.
• W1966393463 cites W1990648368 @default.
• W1966393463 cites W2001322218 @default.
• W1966393463 cites W2018170213 @default.
• W1966393463 cites W2063118337 @default.
• W1966393463 cites W2080130027 @default.
• W1966393463 cites W2094393529 @default.
• W1966393463 cites W2096525808 @default.
• W1966393463 cites W2099882241 @default.
• W1966393463 cites W2109199482 @default.
• W1966393463 cites W2111614444 @default.
• W1966393463 cites W2116096765 @default.
• W1966393463 cites W2130082558 @default.
• W1966393463 cites W2135165654 @default.
• W1966393463 cites W2138904885 @default.
• W1966393463 cites W2141214343 @default.
• W1966393463 cites W2146630930 @default.
• W1966393463 cites W2158294771 @default.
• W1966393463 cites W2160879512 @default.
• W1966393463 cites W2162905192 @default.
• W1966393463 cites W2157118050 @default.
• W1966393463 doi "https://doi.org/10.1016/j.ophtha.2009.04.041" @default.
• W1966393463 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19744717" @default.
• W1966393463 hasPublicationYear "2009" @default.
• W1966393463 type Work @default.
• W1966393463 sameAs 1966393463 @default.
• W1966393463 citedByCount "37" @default.
• W1966393463 countsByYear W19663934632012 @default.
• W1966393463 countsByYear W19663934632013 @default.
• W1966393463 countsByYear W19663934632014 @default.
• W1966393463 countsByYear W19663934632015 @default.
• W1966393463 countsByYear W19663934632016 @default.
• W1966393463 countsByYear W19663934632018 @default.
• W1966393463 countsByYear W19663934632019 @default.
• W1966393463 countsByYear W19663934632020 @default.
• W1966393463 countsByYear W19663934632021 @default.
• W1966393463 crossrefType "journal-article" @default.
• W1966393463 hasAuthorship W1966393463A5014277100 @default.
• W1966393463 hasAuthorship W1966393463A5020252832 @default.
• W1966393463 hasAuthorship W1966393463A5021420755 @default.
• W1966393463 hasAuthorship W1966393463A5030170309 @default.
• W1966393463 hasAuthorship W1966393463A5031739654 @default.
• W1966393463 hasAuthorship W1966393463A5037773842 @default.
• W1966393463 hasAuthorship W1966393463A5043697434 @default.
• W1966393463 hasAuthorship W1966393463A5056077950 @default.
• W1966393463 hasAuthorship W1966393463A5070236238 @default.
• W1966393463 hasAuthorship W1966393463A5075952432 @default.
• W1966393463 hasAuthorship W1966393463A5080095497 @default.
• W1966393463 hasAuthorship W1966393463A5083184324 @default.
• W1966393463 hasConcept C126322002 @default.
• W1966393463 hasConcept C141071460 @default.
• W1966393463 hasConcept C142724271 @default.
• W1966393463 hasConcept C203014093 @default.
• W1966393463 hasConcept C2777034029 @default.
• W1966393463 hasConcept C2777391075 @default.
• W1966393463 hasConcept C2778907293 @default.
• W1966393463 hasConcept C2780122209 @default.
• W1966393463 hasConcept C2780133432 @default.
• W1966393463 hasConcept C2908647359 @default.
• W1966393463 hasConcept C501593827 @default.
• W1966393463 hasConcept C71924100 @default.
• W1966393463 hasConcept C86803240 @default.
• W1966393463 hasConcept C89423630 @default.
• W1966393463 hasConcept C99454951 @default.
• W1966393463 hasConceptScore W1966393463C126322002 @default.
• W1966393463 hasConceptScore W1966393463C141071460 @default.
• W1966393463 hasConceptScore W1966393463C142724271 @default.
• W1966393463 hasConceptScore W1966393463C203014093 @default.
• W1966393463 hasConceptScore W1966393463C2777034029 @default.
• W1966393463 hasConceptScore W1966393463C2777391075 @default.
• W1966393463 hasConceptScore W1966393463C2778907293 @default.
• W1966393463 hasConceptScore W1966393463C2780122209 @default.
• W1966393463 hasConceptScore W1966393463C2780133432 @default.
• W1966393463 hasConceptScore W1966393463C2908647359 @default.
• W1966393463 hasConceptScore W1966393463C501593827 @default.
• W1966393463 hasConceptScore W1966393463C71924100 @default.
• W1966393463 hasConceptScore W1966393463C86803240 @default.

• next